Radiotherapy Device Market Size, Share, Analysis and Forecasts, 2016 to 2022
- Submitted by: Marketreport
- Views: 42
- Category: Other
- Date Submitted: 10/12/2016 12:09 AM
- Pages: 3
- Report this Essay
According to Stratistics MRC, the Global Radiotherapy Device market is accounted for $5.5 billion in 2015 and is expected to reach $9.1 billion by 2022 growing at a CAGR of 7.4% from 2015 to 2022. Radiotherapy being a painless treatment, increase in cancer patients and sophisticated diagnostic techniques are accelerating the market growth. The multiple side-effects of radiation therapy and shortage of trained personnel could hamper radiotherapy devices market growth. However, challenges in visualizing tumours will limit the radiotherapy device market growth.
External beam therapy is accounted for maximum share of the global radiotherapy market, followed by internal radiotherapy devices and systemic radiotherapy due to a high installation contracts for the Proton Therapy Device Segment. The prostate cancer application segment is expected to witness largest share in both external and internal radiotherapy market. North America is the largest market for radiotherapy devices followed by Europe. Asia-Pacific is expected to grow at the fastest rate during the forecast period due to improving healthcare infrastructure and favourable government activities.
Browse full report with TOC@ https://marketreportscenter.com/reports/415449/radiotherapy-device-global-market-outlook-2016-2022
Some of the key players in global Radiotherapy Device market are Accuray Incorporated, Coviden Plc., IBA Group, GE Healthcare, Elekta AB, IsoRay Medical, Inc., Nordion, Inc., RaySearch Laboratories AB, Mevion Medical Systems, Inc, Mitsubishi Electric Corporation, Protom International Inc, Siemens Healthcare, C.R. BARD, Inc. Angiodynamics Inc, Toshiba Medical Systems Corporation, Shenzhen GeneMDx Biotech. Co., Ltd., Varian Medical Systems, Inc., IntraOp Medical, Inc, Theragenics Corporation, Vision RT Ltd, Koninklijke Philips N.V, Eckert & Ziegler BEBIG, Oncura, Inc. and Sirtex Medical Ltd.
Products Covered:
Internal Beam Radiotherapy
o Cesium-131
o Iodine-125
o Palladium-103...
External beam therapy is accounted for maximum share of the global radiotherapy market, followed by internal radiotherapy devices and systemic radiotherapy due to a high installation contracts for the Proton Therapy Device Segment. The prostate cancer application segment is expected to witness largest share in both external and internal radiotherapy market. North America is the largest market for radiotherapy devices followed by Europe. Asia-Pacific is expected to grow at the fastest rate during the forecast period due to improving healthcare infrastructure and favourable government activities.
Browse full report with TOC@ https://marketreportscenter.com/reports/415449/radiotherapy-device-global-market-outlook-2016-2022
Some of the key players in global Radiotherapy Device market are Accuray Incorporated, Coviden Plc., IBA Group, GE Healthcare, Elekta AB, IsoRay Medical, Inc., Nordion, Inc., RaySearch Laboratories AB, Mevion Medical Systems, Inc, Mitsubishi Electric Corporation, Protom International Inc, Siemens Healthcare, C.R. BARD, Inc. Angiodynamics Inc, Toshiba Medical Systems Corporation, Shenzhen GeneMDx Biotech. Co., Ltd., Varian Medical Systems, Inc., IntraOp Medical, Inc, Theragenics Corporation, Vision RT Ltd, Koninklijke Philips N.V, Eckert & Ziegler BEBIG, Oncura, Inc. and Sirtex Medical Ltd.
Products Covered:
Internal Beam Radiotherapy
o Cesium-131
o Iodine-125
o Palladium-103...